Overview

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

Status:
Completed

Trial end date:
2021-09-09

Target enrollment:

Participant gender:

Summary

This trial is to establish bioequivalence of the fixed dose combination (FDC) tablets (containing 12.5 mg empagliflozin/850 mg metformin) (Test, T) compared with the single tablets (10 mg empagliflozin and Glifage® 850 mg tablets) (Reference, R).

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Empagliflozin
Metformin